Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
For beneficiaries to be eligible under the BALANCE Model, providers must attest that they meet certain clinical criteria, including qualifying for a GLP-1 for a currently covered use (such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea) or for use to treat obesity based on similar clinical criteria as applied in the Medicare GLP-1 Bridge (Figure 3)
Developed by Eli Lilly, this compound activates three distinct metabolic hormone receptors simultaneously, earning it the designation of triple agonist in clinical literature
Orforglipron represents the oral GLP-1 frontier, potentially eliminating the need for injections altogether
Conservazione Conservare il prodotto in luogo fresco ed asciutto ad una temperatura non superiore a 25C
Louisiana Bill Expands Medicaid Coverage for GLP-1 Receptor Agonists Family medicine clinicians managing GLP-1 therapy face significant barriers to treatment initiation due to formulary restrictions and coverage limitations across payers, with Medicare explicitly excluding obesity indications and many state Medicaid programs restricting access despite clinical efficacy
The dose is also available through GoodRx for $399 per month
US$ 29.96
US$ 27.29
US$ 24.60
US$ 23.75
US$ 28.73
US$ 20.94
US$ 28.13
US$ 21.69
